YU42603A - Laktamska jedinjenja i njihova farmaceutska primena - Google Patents

Laktamska jedinjenja i njihova farmaceutska primena

Info

Publication number
YU42603A
YU42603A YU42603A YUP42603A YU42603A YU 42603 A YU42603 A YU 42603A YU 42603 A YU42603 A YU 42603A YU P42603 A YUP42603 A YU P42603A YU 42603 A YU42603 A YU 42603A
Authority
YU
Yugoslavia
Prior art keywords
diabetic
lactam compounds
pharmaceutical use
glucose
preventives
Prior art date
Application number
YU42603A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Yukio Iino
Takao Ikenoue
Hiroyuki Matsueda
Toshihiro Hatanaka
Ryusuke Hirama
Yoko Masuzawa
Akiyo Yamazaki
Nobuo Kondo
Fumio Ohta
Original Assignee
Ajinomoto Co.Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co.Inc. filed Critical Ajinomoto Co.Inc.
Publication of YU42603A publication Critical patent/YU42603A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
YU42603A 2000-12-01 2001-11-29 Laktamska jedinjenja i njihova farmaceutska primena YU42603A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01

Publications (1)

Publication Number Publication Date
YU42603A true YU42603A (sh) 2006-03-03

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
YU42603A YU42603A (sh) 2000-12-01 2001-11-29 Laktamska jedinjenja i njihova farmaceutska primena

Country Status (26)

Country Link
US (3) US7153850B2 (https=)
EP (1) EP1346993B1 (https=)
JP (2) JP3826400B2 (https=)
KR (1) KR100826818B1 (https=)
CN (2) CN100577651C (https=)
AT (1) ATE446297T1 (https=)
AU (3) AU1850202A (https=)
BG (1) BG107857A (https=)
BR (1) BR0115852A (https=)
CA (1) CA2430124C (https=)
CZ (1) CZ20031520A3 (https=)
DE (1) DE60140270D1 (https=)
ES (1) ES2331299T3 (https=)
HU (1) HUP0400806A3 (https=)
IL (1) IL156158A0 (https=)
MX (1) MXPA03004876A (https=)
NO (1) NO325401B1 (https=)
NZ (1) NZ526164A (https=)
PL (1) PL362835A1 (https=)
RU (1) RU2287530C2 (https=)
SK (1) SK6582003A3 (https=)
TW (1) TWI241302B (https=)
UA (1) UA76969C2 (https=)
WO (1) WO2002044180A1 (https=)
YU (1) YU42603A (https=)
ZA (1) ZA200304100B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL362835A1 (en) * 2000-12-01 2004-11-02 Ajinomoto Co,Inc. Lactam compounds and medicinal use thereof
CN1771040B (zh) * 2003-02-07 2010-06-16 味之素株式会社 糖尿病治疗药
CA2544310A1 (en) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
JPWO2005068467A1 (ja) 2004-01-14 2007-12-27 味の素株式会社 新規縮環化合物
KR100858262B1 (ko) * 2004-10-13 2008-09-11 에프. 호프만-라 로슈 아게 Cdk2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀
NZ563131A (en) 2005-04-28 2010-09-30 Ajinomoto Kk Tricyclic lactam compound as a hypoglycemic agent
EP2157092A4 (en) * 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008136392A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. 経口投与用製剤
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
RU2017126027A (ru) * 2014-12-22 2019-01-24 ЕА Фарма Ко., Лтд. Лекарственное средство для лечения расстройств эпителия роговицы
CA3011538A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamantane derivatives for the treatment of filovirus infection
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
JP7566338B2 (ja) * 2019-01-23 2024-10-15 ▲たん▼解生醫股分有限公司 グルコース代謝障害の長時間作用型の予防または治療に使用するためのβ-ラクタム化合物またはその塩

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
AU8592598A (en) 1997-07-30 1999-02-22 Wyeth Tricyclic vasopressin agonists
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
PL362835A1 (en) * 2000-12-01 2004-11-02 Ajinomoto Co,Inc. Lactam compounds and medicinal use thereof
CN1771040B (zh) * 2003-02-07 2010-06-16 味之素株式会社 糖尿病治疗药

Also Published As

Publication number Publication date
US7632830B2 (en) 2009-12-15
KR20030051893A (ko) 2003-06-25
ZA200304100B (en) 2004-08-22
EP1346993A4 (en) 2005-12-21
US7153850B2 (en) 2006-12-26
RU2287530C2 (ru) 2006-11-20
CA2430124A1 (en) 2002-06-06
JP2006213732A (ja) 2006-08-17
NO20032439L (no) 2003-07-18
BR0115852A (pt) 2003-12-23
HUP0400806A3 (en) 2007-11-28
AU2006241377A1 (en) 2006-12-14
BG107857A (bg) 2004-06-30
ES2331299T3 (es) 2009-12-29
DE60140270D1 (de) 2009-12-03
WO2002044180A1 (en) 2002-06-06
NO325401B1 (no) 2008-04-21
HUP0400806A2 (hu) 2004-07-28
JPWO2002044180A1 (ja) 2004-04-02
ATE446297T1 (de) 2009-11-15
EP1346993B1 (en) 2009-10-21
US20080096862A1 (en) 2008-04-24
CN100577651C (zh) 2010-01-06
UA76969C2 (en) 2006-10-16
TWI241302B (en) 2005-10-11
CN1269818C (zh) 2006-08-16
NZ526164A (en) 2004-09-24
US20040048847A1 (en) 2004-03-11
CN1487940A (zh) 2004-04-07
US7326701B2 (en) 2008-02-05
AU2006241377B2 (en) 2009-01-08
IL156158A0 (en) 2003-12-23
JP4505753B2 (ja) 2010-07-21
SK6582003A3 (en) 2003-09-11
PL362835A1 (en) 2004-11-02
MXPA03004876A (es) 2004-01-27
JP3826400B2 (ja) 2006-09-27
CN1911915A (zh) 2007-02-14
CZ20031520A3 (cs) 2003-10-15
EP1346993A1 (en) 2003-09-24
CA2430124C (en) 2011-01-11
NO20032439D0 (no) 2003-05-28
KR100826818B1 (ko) 2008-05-02
US20060189597A1 (en) 2006-08-24
AU2002218502B2 (en) 2006-09-21
AU1850202A (en) 2002-06-11

Similar Documents

Publication Publication Date Title
YU42603A (sh) Laktamska jedinjenja i njihova farmaceutska primena
MXPA03007712A (es) Sales farmaceuticas.
IL138767A0 (en) Anticancer compositions
CA2327973A1 (en) Storage system for powdered pharmaceuticals, and inhaler equipped with this system
WO2002007712A3 (en) Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
WO2007081949A3 (en) Small-volume oral transmucosal dosage forms
SI1169024T1 (sl) Predzelatinirani skrob v formulaciji s kontroliranim sproscanjem
EP1295609A4 (en) MEDICINES WITH MIXED ACTIVE SUBSTANCES
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
WO2001082897A3 (en) Liposome drug delivery
WO2005007137A3 (de) Ambroxolhaltige tabletten
MXPA04002510A (es) Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria.
WO2003032946A3 (en) Ph-sensitive liposomes for targeted drug delivery
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
WO2004026319A3 (en) Pharmaceutical compositions increasing camp useful for the treatment of cancers
WO2005110358A3 (de) Filmförmiges, oral zu verabreichendes arzneimittel, enthaltend estriol
MY153696A (en) Solid pharmaceutical formulation
WO2001037818A3 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
WO2005020968A3 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
PL373758A1 (en) Synergistic interaction of abacavir and alovudine
WO2004007522A3 (fr) Composes a base d'hormone donneurs de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
WO2002049647A3 (fr) Nouvelle application therapeutique d'un derive de la thienylcyclohexylamine
ZA200204331B (en) Pharmaceutical composition for controlled drug delivery system.
ZA200110073B (en) 14β-H-Sterols, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments.